Burkitt's lymphoma (BL) was initially described as an African disease with particular epidemiological characteristics which suggest than an infective agent plays a role in its aetiology (Burkitt, 1958 (Burkitt, , 1962 .
Morphological studies showed later that lymphomas with similar histopathological features occur in other parts of the world (O'Conor, 1965) , but occur with a much lower incidence. According to a recent international working formulation, they belong to the group of small non-cleaved, highgrade non-Hodgkin's lymphomas (NHML) (Rosenberg et al., 1982) .
Whereas the clinical presentation differs markedly from high-to low-incidence areas (jaw predominance versus abdominal masses), these rapidly growing tumours are very chemo-sensitive, and rapid progress in treatment has been made during the last years, reaching cure rates close to 70% (Bowman et al., 1982; Patte et al., 1982) .
The Epstein-Barr virus (EBV), initially isolated from an African BL tumour line (Epstein et al., 1964) , can be considered as one of the causative agents for BL cases occuring in high-incidence central African regions (de The, 1978) , where 96% of tumours harbour the viral genome (Geser et al., 1983) . However, in low-incidence areas, most BL tumours do not contain viral markers, and other risk factors must be identified. Very recently it was suggested that a crucial step in the development of the malignant process is represented by the chromosomal translocations found in BL tumours, independent of their geographic origin. Furthermore, these translocations -of three types: t(8;14), t(8;22) or t(2;8) -might represent the best markers of BL tumours (Berger et al., 1979; Berheim et al., 1981) .
There have been some detailed descriptions of African BL outside the high-incidence areas: The reports from North Africa that are available are not well documented with regard to virological or cytogenetic studies (Kalbian, 1967; Say et al., 1967; Cammoun et al., 1972; Tinaztere et al., 1973; Cehreli & Tosun, 1975; Capske & Kalifat, 1979) . More detailed data on Arab cases living in Palestine have been published (Hulu et al., 1970; Aghai et al., 1974; Gotlieb-Stematsky et al., 1976; Goldblum et al., 1977; Buchner et al., 1978; Selzer 504 Y. LADJADJ et al. et al., 1979a, b; Prokocimer et al., 1980) , but no significant survival study could be found.
We report here an analysis of 49 cases of Algerian abdominal Burkitt- Murphy (1977) and Ziegler (1977) (Table I) (Patte et al., 1982) . Three were treated by massive therapy followed by autologous marrow transplantation (two in Lyon, one in Paris) Hartemann et al., 1982) .
In all cases complete remission (CR) was defined as complete disappearance of all clinical symptoms and at least a normal abdominal echography.
EBV virological studies were performed on 31 of the 49 patients. Since 1982, one of us (YL) has been sending tumours and sera from Algiers to the International Agency for Research on Cancer (IARC), Lyon (GML) as soon as possible after laparotomy. Serological study was performed at diagnosis or at referral to Lyon (or both).
EBV serology was performed at IARC for 29 patients by the indirect immunofluorescence method (Lenoir et al., 1979) . In 17 cases, EBV nuclear antigen (EBNA) was measured in the tumour cells. Twenty-five Algerian children with other cancers referred to Centre Leon Berard during the same period were studied with regard to EBV status by serology and were used as controls for this study.
BL cases were considered to be EBV-positive only when EBNA was detected within the tumour cells. Probable EBV positive BL was considered for patients with VCA >640 and EA (D+R) >160 according to an IARC study (Geser et al., 1983) , other cases, either without EBNA study on tumour cells or with only serological data, were considered to be negative or probable negative BL (see Tables  III and IV) .
In 10 cases, immunological membrane markers were obtained in Lyon on the tumour cells. In nine cases, a Burkitt continuous cell line was established at IARC (Philip et al., submitted) ; cytogenetic data are available, for these nine cases and for four others (Mark-Vendel et al., 1983) .
Results
The data obtained from our studies of the 49 cases are summarized in Figures 1-6 and Table II. Geographic, sex and age distribution As shown in Figure 1 , most patients were referred from the Mediterranean coast of Algeria. The patients comprised 34 males and 15 females (ratio, 2.26:1).
The age distribution by sex of patients is given in 
Initial presentation
The interval between first symptom and diagnosis was 2.4 months (4 days to 10 months). Referred clinical symptoms were always abdominal tumours, except that two patients had jaw tumours associated with abdominal involvement. At the time of the first clinical examination, complaints of abdominal pain (23/49), vomiting (10/49), diarrhoea or constipation (7/49), fever (6/49), weight loss (4/19), neurological symptoms (2/49) and occlusion (2/49) were noted.
As shown in Table II , by far the most frequent site of presentation was the ileo-caecum (16/49). Small-bowel involvement was seen initially in nine patients with obvious clinical and pathological difference from immunoproliferative small intestinal disease (IPSID). A total of 16 patients presented with diffuse involvement of the intestine. Only one of the 15 females showed an ovarian tumour during laparotomy and systematic examination of the pelvis.
Staging
The Murphy classification (Murphy, 1977) identified (Tables I and II) and II), which is specific for the abdominal form of BL, shows a clear difference between non-extensive disease (AR) and extensive disease (C and D). This difference was associated with wide differences in prognosis (as shown in Figure 4 ). Figure 6 , the majority of deaths were due either to bad general condition at referral or to immediate post-surgical evolution, as described above (in point 2). Bacterial infections and toxicity were other causes of death in this group of patients. Only two patients died after eight months of evolution, and these had been in relapse before the eighth month after diagnosis. Figure 6 Date and cause of the 26 deaths (2 lost for evaluation). 
Discussion
In a recent histopathological study from Algeria (Afiane & Chouiter, 1982) , it was reported that BL represents 46.5% of all childhood NHML, in comparison with the 56% reported by Philip et al. (1980b Philip et al. ( , 1982 and the 45.6% reported by GerardMarchant et al. (1982) in France and the 33% reported by Cosmann & Berard (1980) (Dorfmann, 1965; Levine et al., 1982; Philip et al., 1982) . During the period [1980] [1981] [1982] Abdominal Burkitt-type lymphoma is a clear clinical entity accounting for at least 60% of all Burkitt lymphomas in Algerian children. The age incidence curve, which indicates a peak between 4 and 5 years is surprising in relation to the report of Olweny from Uganda (Olweny et al., 1980) and to reports from other parts of the world (Lenoir et al., 1984) . The peak of BL thus seems to be younger in Algeria than in other countries, although this finding must be confirmed by further reports from this country. Our data allow definition of the characteristics of abdominal BL: patients die very quickly from a particular, explosive form of the disease, whereas all patients alive NED eight months after CR are still alive and can be considered as cured. This finding confirms those of previous reports (Philip et al., 1980a; Patte et al., 1981) . The overall survival of our patients is similar to that of patients from countries with high socioeconomic levels (Philip et.al., 1980; Patte et al., 1981) . Figure 5 , a comparison with previous series from Algiers (0% survival in 1975-1978, see 3), shows the progress made within a short period in our country. The Ziegler classification (Figure 4 ) clearly isolates that group of patients for whom surgery plays a major role in obtaining a good prognosis, although this group could represent a selection, since complete excision is more often proposed for smaller tumours. However, the assumption that "there is no room for surgery in BL" (Patte et al., 1981) should be reviewed, especially in countries with a low economic level where high technology and intensive chemotherapy are not available. This paper is the first to report clear indications of an EBV association in BL from a non-endemic area of Africa. The EBV association as measured by the EBNA test was 88% in 17 cases studied. A probable association based on EBNA and on elevated EBV antibody titres was 80% in 31 cases studied. This is in contrast to the serological data on 25 control subjects with other solid tumours, in whom the GMT for VCA was 120 versus 580 in the BL patients. Similarly the GMT for EA (D + R) was 2 in the controls and 163 in the BL cases. This difference is quite significant (P<0.01) and the value of EA (D + R) for determination of EBV association in BL patients has been previously reported (Geser et al., 1983; Lenoir, unpublished data) .
The incidence of BL among childhood cancers in Algeria is not known, but may be very different than in Europe because BL is believed to be the most common childhood cancer in Algeria (Afiane & Chouiter, 1982) , whereas in France BL account for only 3% of childhood cancer (Philip, unpublished data) . BL in Algeria might represent between equatorial Africa and Europe an intermediate incidence area for BL, and based on this data the relationship between BL incidence and EBV association remains unclear. Our report, however, may indicate socio-economic level is more important than incidence or geography as an explanation of the EBV association with BL. Algeria cannot be considered an endemic region for BL, because of the intermediate incidence and the prevalence of abdominal presentation with intermediate incidence of jaw tumour (17%), but it should be considered as a part of the world with a high EBV association for BL.
It must be emphasized also that the present study gives further examples of typical variant translocations in BL (Mark-Vendel et al., 1983) , and of a complex three-way rearrangement (Philip et al., 1981) .
Algerian BL are comparable to European cases with regard to clinical presentation and evolution and to African cases with regard to EBV association and socio-economic level of the patients. In terms of incidence Algerian BL could be considered as an intermediate area. For these reasons, it appears to be a transitional model for clinical research in BL. Our data strongly indicate that North African countries should be included in future epidemiological, virological, cytogenetical and clinical investigations on BL.
